Dr. Susan M Schneider, M.D., F.A.C.S. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 330 Madison St Ste 104, Joliet, IL 60435 Phone: 815-725-3440 |
Dr. Bernardino Michael Mendez, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1124 Essington Rd, Joliet, IL 60435 Phone: 815-373-1004 Fax: 815-744-3969 |
Dr. Jose Luis Rios, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1124 Essington Rd, Joliet, IL 60435 Phone: 815-744-8554 Fax: 815-744-3969 |
News Archive
New England Biolabs (NEB) has launched a suite of new and validated products designed to simplify DNA methylation analysis for epigenetics researchers. These enzyme-based solutions address some of the challenges of the current methods, including the lack of a reproducible method for the analysis and quantitation of 5-hydroxymethlcytosine (5-hmC) in the epigenome.
Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).
The business of counterfeit prescription drugs "has grown to frightening proportions," and the U.S. must do more to "protect the integrity of pharmaceuticals dispensed" in the nation, Henry Miller, a physician and Hoover Institution fellow, writes in a Washington Times opinion piece.
Rupture of an abdominal aortic aneurysm is one of the most dramatic medical emergencies a person can face. It usually strikes without warning, killing approximately 50 percent of those who experience it before they reach a hospital. Of those who do get to a health facility alive, only about 50 percent survive.
Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker.
› Verified 4 days ago